Nov 2, 2026
Chemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is Effective
Chemomab Therapeutics and Scipher Medicine announced that the SEC has declared effective their Registration Statement on Form S-4 regarding their proposed business combination. A special meeting for Chemomab shareholders is scheduled for December 4, 2026, to vote on the merger, which is expected to close in early 2027. The combined company will operate as Scipher Medicine Corporation and trade under "SCIP" on Nasdaq, focusing on immunology precision medicine with a planned Phase 2 trial for rheumatoid arthritis.
Company relevance
100.00%
Company sentiment
Bullish
Overall sentiment
Bullish
Nov 2, 2026
Chemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is Effective
Chemomab Therapeutics and Scipher Medicine announced that the SEC declared effective the Registration Statement on Form S-4 regarding their proposed business combination. Chemomab shareholders are scheduled to vote on the merger on December 4, 2026, with the transaction expected to close in early 2027. The combined company will be named Scipher Medicine Corporation and plans to initiate a Phase 2 trial for rheumatoid arthritis with nebokitug in the first half of 2027.
Company relevance
100.00%
Company sentiment
Somewhat-Bullish
Overall sentiment
Somewhat-Bullish